LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Increased Bleb Formation Characterizes Metastatic Cancer Cells

By LabMedica International staff writers
Posted on 04 Jun 2019
Image: Left: Images of a blebbing, highly metastatic PC3 prostate cancer cell (top) and a non-blebbing normal RWPE-1 prostate cell being forced into a microfluidic channel. Middle: Outlines of the images on the left highlighting blebbing and cell deformation. Right: Percentage of highly metastatic PC3, moderately metastatic DU145, and normal RWPE-1 cells that bleb while being forced into a channel along with the standard deviation (SD) (Photo courtesy of Fazle Hussain, Texas Tech University).
Image: Left: Images of a blebbing, highly metastatic PC3 prostate cancer cell (top) and a non-blebbing normal RWPE-1 prostate cell being forced into a microfluidic channel. Middle: Outlines of the images on the left highlighting blebbing and cell deformation. Right: Percentage of highly metastatic PC3, moderately metastatic DU145, and normal RWPE-1 cells that bleb while being forced into a channel along with the standard deviation (SD) (Photo courtesy of Fazle Hussain, Texas Tech University).
A recent paper described an inexpensive fluid biopsy device that is able to distinguish highly metastatic prostate cancer cells from moderately metastatic prostate cancer cells and normal cells.

Since most prostate tumor cells that survive current treatment regimens become metastatic, there is an urgent need for new tools to detect metastatic prostate cancer that do not rely on prostate specific antigen (PSA) measurements, which cannot accurately identify cells with metastatic potential.

Plasma membrane blebbing (in which portions of the cell’s outer layer bulges outward from the more rigid inner layer) is known to provide important metastatic capabilities to cancer cells by aiding cell detachment from the primary tumor site and increasing cell deformability to promote cell migration through the extracellular matrix. In fact, highly metastatic prostate cancer cells flowing through a microfluidic channel form 27% more plasma membrane blebs than normal cells and have a lower stiffness (about 50%).

Taking advantage of this property, investigators at Texas Tech University (Lubbock, USA) developed an instrument that measured bleb formation as the device forced cell samples through minute channels less than 10 microns wide. Results obtained by this method revealed that highly metastatic prostate cancer cells exhibited more blebbing than did moderately metastatic or normal cells. Of the highly metastatic cells 56% produced blebs, whereas only 29% of normal cells and 38% of moderately metastatic cells did.

Mechanistically, increased blebbing by highly metastatic cells was attributed to low levels of the protein F-actin, which resulted in a reduced number of binding sites for proteins that normally anchor the cell’s plasma membrane to the inner cortex.

“This is a potentially significant finding which may provide simple and inexpensive diagnostic methods for detecting early and advanced cancer, particularly metastatic cancer,” said senior author Dr. Fazle Hussain, professor of mechanical engineering at Texas Tech University.

The fluid biopsy device for detection of highly metastatic prostate cancer cells was described in the May 21, 2019, online edition of the journal Biomicrofluidics.

Related Links:
Texas Tech University

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Pipette
Accumax Smart Series

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more